DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Weekly Extended Market Report — Review + Week Ahead
Reality check: end-of-year tape can be *weird* (thin liquidity, bigger wicks, sudden squeezes).
Treat moves as “informative” but not always “reliable”.
S&P 500: 6,929.94 (week +1.4%, YTD +17.8%)
Nasdaq: 23,593.10 (week +1.2%, YTD +22.2%)
Dow: 48,710.97 (week +1.2%, YTD +14.5%)
1) Market recap — what happened on the tape
U.S. equities closed slightly lower on Friday (Dec 26) as traders returned from the holiday, with very light participation. Even so, the week finished green across the major indices. The “Santa Claus rally” window is in play, but price action can be noisy with institutions mostly sidelined.
Friday close (Dec 26): S&P 500 -0.1% to 6,929.94; Dow -0.1% to 48,710.97; Nasdaq -0.1% to 23,593.10; Russell 2000 -0.5% to 2,534.35.
Quick weekly scoreboard (week ended Dec 26)
- S&P 500: +1.4% on the week, +17.8% YTD
- Dow: +1.2% on the week, +14.5% YTD
- Nasdaq: +1.2% on the week, +22.2% YTD
- Russell 2000: +0.2% on the week, +13.6% YTD
Why it matters: year-end “marking,” tax-driven flows, and reduced liquidity can exaggerate both breakouts and fake-outs.
2) Macro snapshot — the three numbers to remember
U.S. GDP (Q3 2025): initial estimate
Real GDP increased at an annual rate of 4.3% in Q3 2025 (initial estimate).
Durable goods (Oct): headline vs. “core” nuance
New orders for manufactured durable goods in October fell 2.2% (headline). This series can whipsaw on aircraft/transportation, so the market often looks for underlying investment signals in “core” measures.
Consumer confidence (Dec): demand/softening signal
The Conference Board Consumer Confidence Index fell to 89.1 in December (from 92.9), extending a multi-month decline.
Trump factor (markets angle, not politics)
The “Trump factor” this week stayed mostly about tariffs, trade headlines, and second-order inflation implications. One widely cited data point: the effective U.S. tariff rate in 2025 was reported as peaking in April and still very elevated later in the year.
Translation for traders: tariff headlines can hit (1) inflation expectations, (2) margins, (3) supply chain assumptions, and (4) cross-border retaliation risk — often fast.
3) Listed-company news radar — what moved / what people watched
Big caps / major names
- Nvidia (NVDA): moved on a report tied to licensing chip tech (thin tape amplified the move).
- Target (TGT): popped on activist-investor stake chatter.
“Narrative momentum” name
- Rocket Lab (RKLB): extended a major rally after a successful launch + defense/Space Force contract headlines; also saw analyst target talk.
Commodities check
- Gold & silver: continued rising; silver was reported up nearly ~8% for the week, with “supply constraints” noted in mainstream coverage.
- Oil: U.S. crude fell ~2.8% on Friday.
This is the exact kind of week where “headline → price” can be more violent than “fundamentals → price”. Use smaller sizing and wider logic.
4) Geopolitics — the big 3 threads
Ukraine / Russia
Reuters reported Ukraine’s President Zelenskiy planned to meet President Trump to discuss territory and security guarantees. The broader risk channel remains: escalation headlines → energy/risk-off → defense and commodity knock-ons.
Asia (Thailand / Cambodia)
Thailand and Cambodia agreed to a ceasefire after weeks of border fighting, per Reuters.
Trade friction (China / EU)
China announced provisional duties on certain EU dairy products, with tariffs reported up to ~42.7% (seen as retaliation in broader trade tensions).
5) Week ahead — macro + Fed calendar (ET)
Holiday week setup: markets are open on Dec 29–31, closed on Jan 1, and reopen Jan 2. (Bond market early-close timing can differ — check your broker/calendar.)
| Date | Time (ET) | Event | Why traders care |
|---|---|---|---|
| Mon, Dec 29 | 10:00 | Pending Home Sales (Nov) | Housing is still a clean read on rates/affordability; can move rate expectations at the margin. |
| Tue, Dec 30 | 09:00 | S&P/Case-Shiller Home Price Index (Oct) | Price/affordability pulse; often “slow”, but can matter in a rates-sensitive tape. |
| Tue, Dec 30 | 09:45 | Chicago PMI (Dec) | Manufacturing sentiment read; can influence cyclicals and rates micro-moves. |
| Wed, Dec 31 | 14:00 | FOMC Meeting Minutes | Hawk/dove nuance can swing yields, USD, and high-duration equities. |
| Thu, Jan 1 | — | Markets closed (New Year’s Day) | No cash session; watch futures/FX gaps and thin liquidity effects. |
| Fri, Jan 2 | 10:00 | Construction Spending (Nov) | Rates cycle + activity read; can matter more if the market is looking for “growth slowing” confirmation. |
Fed timeline reminder: the Fed’s 2026 meeting schedule shows the next regular FOMC meeting on Jan 27–28, 2026.
6) Week-ahead game plan (high-level)
What can surprise the market?
- Minutes tone shift (Dec 31): any surprise around inflation tolerance, labor, or balance-sheet language.
- Tariffs/trade headlines: sudden escalation/retaliation tends to hit risk fast.
- Thin liquidity spikes: small caps and biotech can make “unreasonable” moves on modest flows.
Risk management vibe (practical)
- Prefer watchlist → DD → small starter, not “all-in before catalysts”.
- If your style is “run-up into the event”: define exit rules before you enter.
- For microcaps: track cash runway + dilution risk as if it’s part of the chart.
Retail flows matter: Reuters flagged that retail inflows into U.S. stocks are set to hit a record in 2025 — which can amplify “crowded narratives” (both up and down).
7) “Hot for next week” watchlists (NOT a buy call)
These are “attention tickers” — the point is: put them on a watchlist, track the catalyst window, and do deeper DD. Prices below are a snapshot from the latest market feed available at publish time.
Healthcare / Biotech (catalyst-driven, higher risk)
| Ticker | Last | Day | Catalyst window | What they’re working on | Why it’s on the radar | Key risk |
|---|---|---|---|---|---|---|
| TRAW High risk | $1.17 | -6.40% | Jan 2026 | Ratutrelvir COVID antiviral (interim vs Paxlovid; final analysis expected Jan 2026). | Microcap “data catalyst” setup + narrative vs incumbent therapy. | Cash/dilution risk + small-N interpretation risk. |
| ACRV High risk | $2.44 | +2.52% | Jan 2026 | Webcast planned with updated interim ACR-368 data + initial ACR-2316 Phase 1 data. | “Information catalyst” (data + roadmap) that can reset expectations. | Clinical read interpretation + financing overhang. |
| GUTS High risk | $2.27 | +0.44% | Jan 2026 | Revita procedure; REMAIN-1 Midpoint Cohort 6-month randomized data expected Jan 2026. | Binary-ish data moment for a “metabolic / post-GLP-1” narrative. | Data risk + adoption/regulatory pathway complexity. |
| ATRA High risk | $17.27 | -2.81% | Jan 10, 2026 | Tab-cel (tabelecleucel) for EBV+ PTLD; FDA PDUFA date Jan 10, 2026. | Classic “FDA window” — the tape often heats up into the date. | Regulatory binary + labeling / manufacturing details matter. |
| FBIO High risk | $3.74 | +1.91% | Jan 14, 2026 | CUTX-101 (copper histidinate) for Menkes disease; FDA PDUFA date Jan 14, 2026 after Class 1 NDA resubmission. | Near-term “FDA window” in a rare pediatric disease with Priority Review; tape can heat up into the decision. | Binary regulatory outcome + prior CRL/cGMP history and funding/dilution overhang. |
Small caps (non-healthcare) — “momentum + narrative” basket
| Ticker | Last | Day | Theme | Why it’s on the radar | Key risk |
|---|---|---|---|---|---|
| AEHR Mid/High | $21.46 | -2.54% | Semiconductor test (AI/advanced chips) | Highlighted in “AI & quantum small-cap” watchlist coverage; can benefit from capex narrative. | Chip-cycle volatility + small-cap multiple compression risk. |
| PLAB Mid | $33.73 | +0.18% | Photomasks / semiconductor manufacturing | Another name cited in small-cap AI/quantum “enablers” discussions. | Cycle sensitivity; “good company, bad tape” risk. |
| SKYT Mid | $18.18 | +1.73% | U.S. foundry / specialized chips | Watchlist candidate in small-cap AI/quantum commentary; narrative can spike fast in thin liquidity. | Execution risk + sentiment-driven drawdowns. |
| USAR High risk | $13.51 | -7.12% | Rare earth / strategic materials | Momentum attention via RS rating coverage + “supply security” macro narrative. | High volatility + headlines; financing/story-risk typical of the space. |
| SIDU High risk | $1.93 | -13.06% | Space/defense microcap + retail chatter | Huge retail message volume / momentum coverage; extremely high volume days. | Dilution/offerings + violent reversals; treat like a “trading vehicle”, not an “investment” by default. |
How to use these watchlists (simple, disciplined)
- Define the catalyst: what date, what deliverable, what “success” looks like.
- Map the risk: cash runway, dilution risk, float/short dynamics, and “binary” exposure.
- Plan the trade: if you’re a “run-up” trader, decide in advance whether you hold through the event.
- Keep receipts: save the primary sources (press release, SEC filing) for each claim.
Sources (primary / high-signal links)
These are the reference links used to verify key points (indices, calendar, macro, catalysts, and major news).
Market performance + holiday schedule
- AP market wrap / index levels (Dec 26): https://www.smdailyjournal.com/business/how-major-us-stock-indexes-fared-friday-12-26-2025/article_90d33bab-f61a-5d02-bafc-aaedfffcdedb.html
- NYSE hours & calendars: https://www.nyse.com/markets/hours-calendars
- Nasdaq market holiday schedule (2026): https://www.nasdaq.com/market-activity/stock-market-holiday-schedule
- Investopedia holiday trading schedule explainer: https://www.investopedia.com/is-the-stock-market-open-for-new-year-s-here-s-the-holiday-trading-schedule-11866762
Macro data
- BEA GDP Q3 2025 (initial estimate): https://www.bea.gov/news/2025/gross-domestic-product-3rd-quarter-2025-initial-estimate-and-corporate-profits
- U.S. Census — Durable Goods (advance report): https://www.census.gov/manufacturing/m3/adv/current/index.html
- Conference Board — Consumer Confidence: https://www.conference-board.org/topics/consumer-confidence/
Fed calendar + week-ahead releases
- Federal Reserve — FOMC meeting calendars (includes 2026 dates): https://www.federalreserve.gov/monetarypolicy/fomccalendars.htm
- Scotiabank — December 2025 economic release calendar (includes week of Dec 29 + FOMC minutes time): https://www.scotiabank.com/ca/en/about/economics/economics-publications/post.other-publications.calendar-of-economic-release-dates.calendar-of-economic-release-dates–december-2025-.html
Geopolitics / trade
- Reuters — Zelenskiy planned meeting with Trump (Dec 26): https://www.reuters.com/world/europe/zelenskiy-says-he-will-meet-trump-sunday-discuss-ukraine-territory-guarantees-2025-12-26/
- Reuters — Thailand/Cambodia ceasefire (Dec 27): https://www.reuters.com/world/asia-pacific/thailand-cambodia-sign-ceasefire-agreement-cambodian-defence-ministry-says-2025-12-27/
- Reuters — China provisional duties on EU dairy (Dec 22): https://www.reuters.com/world/china/china-impose-provisional-duties-up-427-eu-dairy-products-2025-12-22/
- AP — tariffs impact / effective tariff rate discussion (Dec 26): https://apnews.com/article/trump-tariffs-economy-liberation-day-d3458da225c1fdfade97ed494b23e868
Retail flows + notable company headlines
- Reuters — retail investors record year (Dec 23): https://www.reuters.com/business/retail-investors-have-more-sway-over-wall-street-after-record-year-2025-12-23/
- Reuters — post-holiday tape + NVDA/TGT mention (Dec 26): https://www.reuters.com/world/africa/futures-subdued-thin-post-christmas-trading-2025-12-26/
- Investopedia — Rocket Lab rally + contract: https://www.investopedia.com/this-space-stock-extends-its-recent-rally-after-a-successful-launch-space-force-contract-rklb-11874209
Healthcare catalyst sources
- TRAW interim data / final analysis expected Jan 2026: https://www.stocktitan.net/news/TRAW/traws-pharma-reports-positive-interim-clinical-data-with-ratutrelvir-vjzry0isw89w.html
- ACRV January 2026 webcast announcement: https://www.globenewswire.com/news-release/2025/12/17/3207073/0/en/UPDATE-Acrivon-Therapeutics-to-Announce-Clinical-Update-on-its-Ongoing-Phase-2b-Studies-and-Planned-Confirmatory-Phase-3-Trial-for-ACR-368-Initial-Clinical-Data-on-ACR-2316-and-Oth.html
- GUTS REMAIN-1 data timing (Jan 2026): https://www.globenewswire.com/news-release/2025/12/02/3197747/0/en/Fractyl-Health-Reports-Positive-6-Month-REVEAL-1-Open-Label-Results-Showing-Sustained-Post-GLP-1-Weight-Maintenance-After-a-Single-Revita-Procedure.html
- ATRA PDUFA date (company update): https://investors.atara.com/news-releases/news-release-details/atara-biotherapeutics-provides-business-update-2025
- FBIO CUTX-101 resubmission & Jan 14, 2026 PDUFA date (company press release): https://www.globenewswire.com/news-release/2025/12/15/3205379/0/en/Fortress-Biotech-and-Cyprium-Therapeutics-Announce-FDA-Acceptance-of-CUTX-101-NDA-Resubmission.html
Small-cap watchlist sources
- AEHR/PLAB/SKYT small-cap AI/quantum watchlist commentary: https://www.investing.com/analysis/ai-and-quantums-next-big-winners-3-smallcap-stocks-to-watch-in-2026-200671677
- USAR RS rating coverage: https://www.investors.com/ibd-data-stories/usa-rare-earth-reaches-80-plus-relative-strength-rating-benchmark/
- SIDU retail chatter / monthly move: https://stocktwits.com/news-articles/markets/equity/sidus-space-stock-is-up-218-percent-this-month-retail-investors-still-bullish/cLeUaPpREws
Disclosure: This page is informational/educational and is not investment advice. Markets can move fast; always verify primary sources and consider your own risk tolerance.
Report Settimanale Esteso — Recap + Settimana Prossima
Reality check: fine anno = mercato spesso “strano” (liquidità bassa, spike, squeezes).
Le candele possono essere più “rumorose” che “pulite”.
S&P 500: 6.929,94 (settimana +1,4%, YTD +17,8%)
Nasdaq: 23.593,10 (settimana +1,2%, YTD +22,2%)
Dow: 48.710,97 (settimana +1,2%, YTD +14,5%)
1) Recap mercato — cosa si è visto sul tape
Le azioni USA hanno chiuso leggermente negative venerdì (26 Dic) nel rientro post-festivo, con volumi ridotti. Nonostante questo, la settimana è rimasta positiva sui principali indici. La finestra del “Santa Claus rally” c’è, ma con istituzionali spesso “out” le dinamiche possono diventare più caotiche.
Chiusura di venerdì (26 Dic): S&P 500 -0,1% a 6.929,94; Dow -0,1% a 48.710,97; Nasdaq -0,1% a 23.593,10; Russell 2000 -0,5% a 2.534,35.
Tabellone veloce (settimana chiusa il 26 Dic)
- S&P 500: +1,4% settimanale, +17,8% da inizio anno
- Dow: +1,2% settimanale, +14,5% da inizio anno
- Nasdaq: +1,2% settimanale, +22,2% da inizio anno
- Russell 2000: +0,2% settimanale, +13,6% da inizio anno
Perché conta: fine anno = “marking”, flussi fiscali e liquidità ridotta possono amplificare sia breakout veri che falsi segnali.
2) Macro snapshot — i 3 numeri da ricordare
PIL USA (Q3 2025): stima iniziale
Il PIL reale USA è cresciuto a un tasso annualizzato del 4,3% nel Q3 2025 (stima iniziale).
Durable goods (Ottobre): headline vs “core”
Nuovi ordini di beni durevoli in ottobre: -2,2% (headline). Occhio: la componente trasporti/aerei può “sporcare” il dato; spesso il mercato guarda anche le metriche più “core”.
Consumer confidence (Dicembre): segnale domanda
Indice Conference Board sceso a 89,1 a dicembre (da 92,9), proseguendo una fase di debolezza.
Trump factor (angolo mercati, non politica)
Il “Trump factor” questa settimana è stato soprattutto dazi, trade headlines e implicazioni su inflazione/margini. Un punto dati citato spesso: il tasso effettivo dei dazi USA nel 2025 è stato riportato come molto elevato rispetto agli standard storici.
Traduzione pratica: headline sui dazi impattano rapidamente aspettative su inflazione, margini aziendali, supply chain e rischio ritorsioni.
3) News “società quotate” — cosa si è guardato
Big caps / nomi principali
- Nvidia (NVDA): movimento legato a news su licensing/tech (con tape sottile l’effetto è più forte).
- Target (TGT): salita su voci di partecipazione di un attivista.
Nome “narrativa + momentum”
- Rocket Lab (RKLB): estensione rally dopo launch riuscito + news su contratto defense/Space Force e target analisti.
Commodities
- Oro & argento: ancora in salita; l’argento riportato ~+8% nella settimana (vincoli di offerta citati nei media).
- Petrolio: crude USA -2,8% nella seduta di venerdì.
Settimane così: spesso “headline → prezzo” è più violento di “fondamentali → prezzo”. Quindi sizing più piccolo e logica più solida.
4) Geopolitica — 3 filoni principali
Ucraina / Russia
Reuters ha riportato che Zelenskiy pianificava un incontro con il Presidente Trump per discutere territorio e garanzie di sicurezza. Canale rischio: escalation → risk-off → effetti su energia/defense/commodities.
Asia (Thailandia / Cambogia)
Thailandia e Cambogia hanno concordato un cessate il fuoco dopo settimane di scontri, secondo Reuters.
Trade (Cina / UE)
La Cina ha annunciato dazi provvisori su alcuni prodotti lattiero-caseari UE, riportati fino a ~42,7% (in un contesto di tensioni commerciali).
5) Settimana prossima — calendario macro + Fed (ET)
Setup settimana festiva: mercati aperti 29–31 Dic, chiusi 1 Gen, riapertura 2 Gen. (Occhio: bond e orari di chiusura anticipata possono differire.)
| Data | Ora (ET) | Evento | Perché conta |
|---|---|---|---|
| Lun, 29 Dic | 10:00 | Pending Home Sales (Nov) | Housing = termometro pulito su tassi/affordability; può muovere aspettative sui rendimenti. |
| Mar, 30 Dic | 09:00 | S&P/Case-Shiller Home Price Index (Ott) | Dinamiche prezzi case; importante in un tape sensibile ai tassi. |
| Mar, 30 Dic | 09:45 | Chicago PMI (Dic) | Sentiment manifatturiero; può influenzare ciclici e micro-mosse sui tassi. |
| Mer, 31 Dic | 14:00 | FOMC Minutes | Tono hawk/dove → impatto su yields, USD e titoli “duration”. |
| Gio, 1 Gen | — | Mercati chiusi (Capodanno) | Possibili gap (futures/FX) e liquidità sottile. |
| Ven, 2 Gen | 10:00 | Construction Spending (Nov) | Ciclo tassi + attività; può pesare se il mercato cerca conferme di rallentamento. |
Promemoria Fed: calendario ufficiale 2026 → prossimo meeting regolare 27–28 Gen 2026.
6) Piano operativo (high-level)
Cosa può “sorprendere”
- Tono minutes (31 Dic): nuance su inflazione, lavoro, bilancio Fed.
- Headline trade/dazi: escalation/ritorsioni spesso colpiscono subito il rischio.
- Liquidità bassa: small cap e biotech possono muoversi “troppo” per flussi piccoli.
Risk management (pratico)
- Meglio watchlist → DD → starter piccolo, non “all-in” vicino ai catalyst.
- Se fai “run-up”: decidi prima se tieni oltre l’evento.
- Microcap: considera runway cassa + rischio diluizione parte integrante del setup.
Nota flussi: Reuters segnala che i flussi retail nel 2025 sono su livelli record — e questo può amplificare le narrative (in su e in giù).
7) Watchlist “calde” per la prossima settimana (NON è un buy call)
Qui l’idea è: attenzionarli, metterli in watchlist, monitorare la finestra catalyst e fare DD più profonda. I prezzi sono uno snapshot dal feed di mercato disponibile al momento della pubblicazione.
Healthcare / Biotech (catalyst-driven, rischio alto)
| Ticker | Last | Day | Finestra catalyst | Cosa stanno ricercando | Perché in radar | Rischio chiave |
|---|---|---|---|---|---|---|
| TRAW Rischio alto | $1,17 | -6,40% | Gen 2026 | Ratutrelvir antivirale COVID (interim vs Paxlovid; final analysis attesa a Gen 2026). | Microcap “data catalyst” + narrativa alternativa all’incumbent. | Cassa/diluizione + rischio interpretazione small-N. |
| ACRV Rischio alto | $2,44 | +2,52% | Gen 2026 | Webcast con update interim ACR-368 + dati iniziali ACR-2316 Phase 1. | Catalyst “informativo” (dati + roadmap) che può resettare le aspettative. | Lettura dati + possibile overhang finanziario. |
| GUTS Rischio alto | $2,27 | +0,44% | Gen 2026 | Revita; dati randomizzati 6 mesi REMAIN-1 Midpoint attesi a Gen 2026. | Momento dati potenzialmente “binary” su narrativa metabolica/post-GLP-1. | Rischio dati + complessità adozione/percorso regolatorio. |
| ATRA Rischio alto | $17,27 | -2,81% | 10 Gen 2026 | Tab-cel (tabelecleucel) per EBV+ PTLD; PDUFA FDA 10 Gen 2026. | Classico “FDA window”: spesso scalda il tape in avvicinamento alla data. | Binary regolatorio + labeling/manufacturing contano molto. |
| FBIO Rischio alto | $3,74 | +1,91% | 14 Gen 2026 | CUTX-101 (copper histidinate) per il morbo di Menkes; PDUFA FDA il 14 Gen 2026 dopo resubmission Class 1. | “FDA window” ravvicinata in malattia pediatrica rara con Priority Review; il tape può scaldarsi avvicinandosi alla data. | Esito regolatorio binario + storia di CRL/cGMP e possibile overhang di funding/diluizione. |
Small caps (non-healthcare) — “momentum + narrativa”
| Ticker | Last | Day | Tema | Perché in radar | Rischio chiave |
|---|---|---|---|---|---|
| AEHR Medio/Alto | $21,46 | -2,54% | Test semiconduttori (AI/advanced chips) | Citata in watchlist “AI & quantum” small-cap; può beneficiare della narrativa capex. | Volatilità ciclo chip + compressione multipli. |
| PLAB Medio | $33,73 | +0,18% | Photomasks / manifattura chip | Nome “enabler” citato in commenti small-cap AI/quantum. | Sensibilità al ciclo; rischio “buona azienda, cattivo tape”. |
| SKYT Medio | $18,18 | +1,73% | Foundry USA / chip specializzati | Watchlist candidate; in liquidità sottile può fare spike rapidi. | Execution risk + drawdown da sentiment. |
| USAR Rischio alto | $13,51 | -7,12% | Rare earth / materiali strategici | Attenzione su momentum (RS rating) + narrativa “supply security”. | Alta volatilità + rischio headline/finanziario. |
| SIDU Rischio alto | $1,93 | -13,06% | Space/defense microcap + chatter retail | Volumi enormi e sentiment retail molto acceso. | Diluizione/offerte + inversioni violente; di default “trading vehicle”. |
Come usarla bene (semplice e disciplinato)
- Definisci il catalyst: data/trigger, deliverable, cosa sarebbe “positivo”.
- Mappa il rischio: runway cassa, diluizione, float/short, binarietà.
- Scrivi il piano: se fai “run-up”, decidi prima se tieni oltre l’evento.
- Fonte primaria: salva press release/SEC filing per ogni claim.
Fonti (link principali)
Link di riferimento usati per verificare punti chiave (indici, calendario, macro, catalyst e news principali).
Mercato + calendario festività
- AP / livelli indici (26 Dic): https://www.smdailyjournal.com/business/how-major-us-stock-indexes-fared-friday-12-26-2025/article_90d33bab-f61a-5d02-bafc-aaedfffcdedb.html
- NYSE hours & calendars: https://www.nyse.com/markets/hours-calendars
- Nasdaq holiday schedule (2026): https://www.nasdaq.com/market-activity/stock-market-holiday-schedule
- Investopedia (trading schedule Capodanno): https://www.investopedia.com/is-the-stock-market-open-for-new-year-s-here-s-the-holiday-trading-schedule-11866762
Macro
- BEA PIL Q3 2025 (stima iniziale): https://www.bea.gov/news/2025/gross-domestic-product-3rd-quarter-2025-initial-estimate-and-corporate-profits
- U.S. Census — Durable goods: https://www.census.gov/manufacturing/m3/adv/current/index.html
- Conference Board — Consumer confidence: https://www.conference-board.org/topics/consumer-confidence/
Fed + calendario settimana prossima
- Federal Reserve — calendario FOMC (include 2026): https://www.federalreserve.gov/monetarypolicy/fomccalendars.htm
- Scotiabank — calendario uscite Dic 2025 (include week of 29 Dic): https://www.scotiabank.com/ca/en/about/economics/economics-publications/post.other-publications.calendar-of-economic-release-dates.calendar-of-economic-release-dates–december-2025-.html
Geopolitica / trade
- Reuters — incontro Zelenskiy/Trump (26 Dic): https://www.reuters.com/world/europe/zelenskiy-says-he-will-meet-trump-sunday-discuss-ukraine-territory-guarantees-2025-12-26/
- Reuters — cessate il fuoco Thailandia/Cambogia (27 Dic): https://www.reuters.com/world/asia-pacific/thailand-cambodia-sign-ceasefire-agreement-cambodian-defence-ministry-says-2025-12-27/
- Reuters — dazi Cina su dairy UE (22 Dic): https://www.reuters.com/world/china/china-impose-provisional-duties-up-427-eu-dairy-products-2025-12-22/
- AP — impatto dazi (26 Dic): https://apnews.com/article/trump-tariffs-economy-liberation-day-d3458da225c1fdfade97ed494b23e868
Flussi retail + news società
- Reuters — record inflows retail (23 Dic): https://www.reuters.com/business/retail-investors-have-more-sway-over-wall-street-after-record-year-2025-12-23/
- Reuters — tape post-holiday + mention NVDA/TGT (26 Dic): https://www.reuters.com/world/africa/futures-subdued-thin-post-christmas-trading-2025-12-26/
- Investopedia — Rocket Lab rally/contract: https://www.investopedia.com/this-space-stock-extends-its-recent-rally-after-a-successful-launch-space-force-contract-rklb-11874209
Fonti catalyst healthcare
- TRAW (final analysis attesa Gen 2026): https://www.stocktitan.net/news/TRAW/traws-pharma-reports-positive-interim-clinical-data-with-ratutrelvir-vjzry0isw89w.html
- ACRV (webcast Gen 2026): https://www.globenewswire.com/news-release/2025/12/17/3207073/0/en/UPDATE-Acrivon-Therapeutics-to-Announce-Clinical-Update-on-its-Ongoing-Phase-2b-Studies-and-Planned-Confirmatory-Phase-3-Trial-for-ACR-368-Initial-Clinical-Data-on-ACR-2316-and-Oth.html
- GUTS (REMAIN-1 Midpoint dati Gen 2026): https://www.globenewswire.com/news-release/2025/12/02/3197747/0/en/Fractyl-Health-Reports-Positive-6-Month-REVEAL-1-Open-Label-Results-Showing-Sustained-Post-GLP-1-Weight-Maintenance-After-a-Single-Revita-Procedure.html
- ATRA (PDUFA 10 Gen 2026): https://investors.atara.com/news-releases/news-release-details/atara-biotherapeutics-provides-business-update-2025
- FBIO CUTX-101 resubmission e PDUFA 14 Gen 2026 (press release aziendale): https://www.globenewswire.com/news-release/2025/12/15/3205379/0/en/Fortress-Biotech-and-Cyprium-Therapeutics-Announce-FDA-Acceptance-of-CUTX-101-NDA-Resubmission.html
Fonti small-cap
- AEHR/PLAB/SKYT (watchlist AI/quantum): https://www.investing.com/analysis/ai-and-quantums-next-big-winners-3-smallcap-stocks-to-watch-in-2026-200671677
- USAR (RS rating): https://www.investors.com/ibd-data-stories/usa-rare-earth-reaches-80-plus-relative-strength-rating-benchmark/
- SIDU (retail chatter): https://stocktwits.com/news-articles/markets/equity/sidus-space-stock-is-up-218-percent-this-month-retail-investors-still-bullish/cLeUaPpREws
Disclosure: contenuto informativo/educativo, non consulenza finanziaria. Verifica sempre le fonti primarie e valuta la tua tolleranza al rischio.
Scanner for active traders
Try ChartsWatcher free, then unlock 10% OFF with SAVE10
ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.
Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.
Start free – then use SAVE10
No credit card required to start. Apply SAVE10 when upgrading.
Recommended platform
One platform. All your brokers.
Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.
A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.
Get 1 Month Free ➔
Multi-broker workflow + customizable layouts in one platform.
Monica.im – the AI assistant I use every day
If you find value in the work I publish on Merlintrader and want a practical AI assistant for research and writing, you can sign up using this referral link. Click here to try Monica.im and support the site
Find out how I use AI on Merlintrader: AI, retail and Merlintrader
Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.
